Adlai Nortye Group Ltd.
ANLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAdlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. At a $681.3M market cap, Adlai Nortye Group Ltd. ranks as a small-cap company within healthcare. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Market Cap
$681.3M
Beta
1.11
P/E (TTM)
—
P/E (Fwd)
-35.95
EPS (TTM)
$-0.66
EPS (Fwd)
$-0.29
ROE
-20.2%
ROA
-8.7%
Cash
$232.8M
Total Debt
$26.7M
Free CF
-$11.4M
52W Change
540.4%
Annual Financials
Cash vs Debt
Where ANL stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ANL finished 16.63% below its 150-day moving average ($12.45) and 5.55% below its 200-day moving average ($10.99). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ANL overbought or oversold?
At the October 20, 2026 close, ANL's RSI(14) was 27.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $232.8M in cash and $26.7M in debt, ANL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$11.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -20.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Adlai Nortye Group Ltd.'s trajectory.